HDAC and HDAC Inhibitors: Implication in Different Pathological Ailments

Abstract

Histone deacetylases (HDAC) and its inhibitors have been found implicated in various diseased conditions. HDACs regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. They have also been found to regulate the post translational modifications through deacetylation of proteins, and hence are involved in many pathophysiological conditions. Till date, USFDA has approved vorinostat, romidepsin, panobinostat, and belinostat as HDAC inhibitors for the treatment of cancer. Considering their wide role in various diseases, more HDAC inhibitors are being developed for the treatment of other diseases such as Alzheimer’s disease, other neurodegenerative disorders, inflammatory diseases and cardiovascular disorders. This review deals with the role of HDCs in various physiological states, their involvement in different diseases and future implications therein.

Keywords: HDAC, SIRT, Cancer, Alzheimer, Huntingtons, Cardiac ischemia

Cite this Article

Priti Jain. HDAC and HDAC Inhibitors: Implication in Different Pathological Ailments. Research & Reviews: A Journal of Drug Design & Discovery. 2018; 5(3): 35–40p.